Evidence map›Paper›PMID 33650799›Full record

Trial reportMicrobiologyOpen2021

Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.

Yao Chen, Hongxun Yuan, Hui Ye, Zongming Shi, Xin Deng, Xuezhi Zhang, Xikang Hou

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in MicrobiologyOpen, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Novel therapeutic regimens againstFrontiers in microbiology · 2024
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yao ChenTraditional Chinese Medicine (TCM) Department, Peking University International Hospital, Beijing, China.ORCID 0000-0002-4998-5088
Hongxun YuanIntensive Care Unit, Peking University International Hospital, Beijing, China.
Hui YeDepartment of Integrative TCM and Western Medicine, Peking University First Hospital, Beijing, China.
Zongming ShiDepartment of Integrative TCM and Western Medicine, Peking University First Hospital, Beijing, China.
Xin DengDepartment of Integrative TCM and Western Medicine, Peking University First Hospital, Beijing, China.
Xuezhi ZhangTraditional Chinese Medicine (TCM) Department, Peking University International Hospital, Beijing, China.
Xikang HouState Key Laboratory of Environment Criteria and Risk Assessment, Chinese Research Academy of Environmental Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A complete understanding and good adherence are crucial for successful Helicobacter pylori eradication. Proper frequency of reminders might be helpful to both doctors and patients to maintain adherence during treatment. The study was to evaluate the influence of an intensive follow-up system based on a clinical database on H. pylori eradication therapy. A total of 196 eligible patients were equally and randomly divided into an intensive follow-up group and a control group. Both groups were administered bismuth-containing quadruple therapy for 14 days. Patients in the intensive follow-up group were informed of pre-treatment, including the duration and potential adverse events. Subsequently, they received telephone follow-ups on days 3 and 14 and 3 days before the urea breath test (UBT). The time points were automatically reminded by a follow-up system in the established clinical database. The control group was only informed of pre-treatment information. UBT was performed 4 weeks after treatment in both groups to assess the presence of H. pylori. The eradication rate, patient compliance, and adverse events were calculated and compared. The H. pylori eradication rates of the intensive follow-up and control groups were 94.7% (90/95, 95% CI: 90%-99%) and 92.9% (78/84, 95% CI: 87%-98%), respectively, by PP analysis (p = 0.601), and 91.8% (90/98, 95% CI: 86%-97%) and 81.6% (80/98, 95% CI: 74%-89%) by ITT analysis (p = 0.035). Adverse events occurred in 9 intensive follow-up group patients and 12 in the control group. Adherence was 96.9% (95/98) in the intensive follow-up group and 85.7% (84/98) in the control group. Semi-automatic intensive follow-up contributed to a higher eradication rate and adherence to H. pylori treatment.

Indexed as

Drug MonitoringAmoxicillinAnti-Bacterial AgentsBismuthClarithromycinEsomeprazoleHelicobacter InfectionsHelicobacter pyloriHumansProton Pump InhibitorsTreatment OutcomeAmoxicillinAnti-Bacterial AgentsBismuthClarithromycinEsomeprazoleProton Pump Inhibitorsadherencebismuth-containing quadruple therapyfollow-upHelicobacter pylori

Identifiers

PMID33650799
PMCPMC7889822

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.